1. Cell Cycle/DNA Damage Metabolic Enzyme/Protease Anti-infection
  2. HSP Bacterial Influenza Virus Antibiotic
  3. Geldanamycin

Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

For research use only. We do not sell to patients.

Geldanamycin Chemical Structure

Geldanamycin Chemical Structure

CAS No. : 30562-34-6

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
USD 55 In-stock
Solution
10 mM * 1 mL in DMSO USD 55 In-stock
Solid
10 mg USD 50 In-stock
25 mg USD 90 In-stock
50 mg USD 150 In-stock
100 mg USD 250 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 28 publication(s) in Google Scholar

Other Forms of Geldanamycin:

Top Publications Citing Use of Products

    Geldanamycin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Sep;120(9):16254-16263.  [Abstract]

    Caspase 3, caspase 9, cleaved caspase 3, cleaved caspase 9, and β-actin protein expression analyzed by Western blot with the treatment of Geldanamycin.

    Geldanamycin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Sep;120(9):16254-16263.  [Abstract]

    Bcl2, Bax, and β-actin protein expression is analyzed by Western blot with the treatment of Geldanamycin.

    Geldanamycin purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2018 Oct 10.  [Abstract]

    Geldanamycin (GA) attenuatea TNF-α-mediated activation of MAPK and NF-κB signaling pathways.
    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    Geldanamycin is a Hsp90 inhibitor with antimicrobial activity against many Gram-positive and some Gram-negative bacteria. Geldanamycin has anti-influenza virus H5N1 activities.

    IC50 & Target[4]

    HSP90

    1.2 μM (Kd)

    Cellular Effect
    Cell Line Type Value Description References
    A2780 IC50
    0.07 μM
    Compound: 1
    Antiproliferative activity against human A2780 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    Antiproliferative activity against human A2780 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    [PMID: 27476419]
    A-375 IC50
    0.06 μM
    Compound: 1
    Antiproliferative activity against human A375 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    Antiproliferative activity against human A375 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    [PMID: 27476419]
    A-431 IC50
    0.2 μM
    Compound: geldanamycin
    Antiproliferative activity against human A431 cells after 72 hrs
    Antiproliferative activity against human A431 cells after 72 hrs
    [PMID: 20655237]
    A-431 IC50
    40 nM
    Compound: 1, GA
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    Cytotoxicity against human A431 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    A549 IC50
    0.1 μM
    Compound: GA
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells after 72 hrs by SRB assay
    [PMID: 29172085]
    A549 IC50
    0.109 μM
    Compound: Geldanamycin
    Anticancer activity against human A549 cells measured after 72 hrs by SRB assay
    Anticancer activity against human A549 cells measured after 72 hrs by SRB assay
    [PMID: 27283788]
    A549 IC50
    0.15 μM
    Compound: geldanamycin
    Cytotoxicity against human A549 cells after 2 days by AlamarBlue assay
    Cytotoxicity against human A549 cells after 2 days by AlamarBlue assay
    [PMID: 23947794]
    A549 IC50
    0.99 μM
    Compound: GDM
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    A549 IC50
    97 nM
    Compound: 1, GA
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    Cytotoxicity against human A549 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    BGC-823 IC50
    0.11 μM
    Compound: 1
    Antiproliferative activity against human BGC823 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    Antiproliferative activity against human BGC823 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    [PMID: 27476419]
    BGC-823 IC50
    40 nM
    Compound: 1, GA
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    CAKI-1 IC50
    0.056 μM
    Compound: Geldanamycin
    Anticancer activity against human Caki1 cells measured after 72 hrs by SRB assay
    Anticancer activity against human Caki1 cells measured after 72 hrs by SRB assay
    [PMID: 27283788]
    CNE2Z IC50
    0.31 μM
    Compound: GM
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human CNE2Z cells assessed as cell growth inhibition by MTT assay
    [PMID: 32527461]
    HCT-116 EC50
    0.03 μM
    Compound: 1
    Antiproliferative activity against human HCT116 cells measured on day 4 by Cell titer-glo assay
    Antiproliferative activity against human HCT116 cells measured on day 4 by Cell titer-glo assay
    [PMID: 21420297]
    HCT-116 EC50
    0.03 μM
    Compound: 1
    Antiproliferative activity against human HCT116 cells by luminescence assay
    Antiproliferative activity against human HCT116 cells by luminescence assay
    [PMID: 21605975]
    HCT-116 IC50
    0.1 μM
    Compound: 1
    Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    Antiproliferative activity against human HCT116 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    [PMID: 27476419]
    HCT-116 IC50
    0.15 μM
    Compound: Geldanamycin
    Anticancer activity against human HCT116 cells measured after 72 hrs by SRB assay
    Anticancer activity against human HCT116 cells measured after 72 hrs by SRB assay
    [PMID: 27283788]
    HeLa IC50
    > 5 μM
    Compound: Geldanamycin
    Cytotoxicity against human HeLa cells at 72 hrs by MTS assay
    Cytotoxicity against human HeLa cells at 72 hrs by MTS assay
    [PMID: 22162786]
    HeLa IC50
    0.06 μM
    Compound: GA
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    Antiproliferative activity against human HeLa cells after 72 hrs by SRB assay
    [PMID: 27266997]
    HeLa IC50
    798 nM
    Compound: 1, GA
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
    [PMID: 25277067]
    HepG2 IC50
    0.3 μM
    Compound: GDM
    Cytotoxicity against human HepG2 cells by MTT assay
    Cytotoxicity against human HepG2 cells by MTT assay
    [PMID: 23656556]
    HepG2 IC50
    1.74 μM
    Compound: GM
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by MTT assay
    [PMID: 32527461]
    HepG2 IC50
    40 nM
    Compound: 1, GA
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    Huh-7 EC50
    0.25 nM
    Compound: Geldanamycin
    Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis
    Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days by qRT-PCR analysis
    [PMID: 18936191]
    Huh-7 EC50
    1.2 nM
    Compound: Geldanamycin
    Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis
    Antiviral activity against Hepatitis C virus genotype 1b Con1 infected in human HuH7 cells assessed as GAPDH RNA or 18S rRNA level after 3 days selected with 40 nM HCV-796 and 800 nM boceprevir by qRT-PCR analysis
    [PMID: 18936191]
    HUVEC IC50
    19 nM
    Compound: 1, GA
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    Cytotoxicity against HUVEC cells after 72 hrs by MTT assay
    [PMID: 25277067]
    L02 IC50
    141 nM
    Compound: 1, GA
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    Cytotoxicity against human HL7702 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    L6 IC50
    6 μM
    Compound: GA
    Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay
    Cytotoxicity against rat L6 cells after 72 hrs by Alamar Blue assay
    [PMID: 24580531]
    LNCaP IC50
    0.43 μM
    Compound: GA
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    Cytotoxicity against human LNCAP cells after 72 hrs by MTT assay
    [PMID: 25105924]
    LS174T IC50
    0.45 μM
    Compound: GA
    Cytotoxicity against human LS174T cells by MTS assay
    Cytotoxicity against human LS174T cells by MTS assay
    [PMID: 17034135]
    MCF7 IC50
    0.04 μM
    Compound: GDA
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
    Antiproliferative activity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
    [PMID: 25075762]
    MCF7 IC50
    0.0427 μM
    Compound: 1, GDA
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
    Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by MTS/PMS assay
    [PMID: 25756299]
    MCF7 IC50
    0.053 μM
    Compound: Geldanamycin
    Cytotoxicity against human MCF7 cells at 72 hrs by MTS assay
    Cytotoxicity against human MCF7 cells at 72 hrs by MTS assay
    [PMID: 22162786]
    MCF7 IC50
    0.11 μM
    Compound: 1
    Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    Antiproliferative activity against human MCF7 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    [PMID: 27476419]
    MCF7 GI50
    35.6 μM
    Compound: geldanamycin
    Growth inhibition of human MCF7 cells after days by SRB assay
    Growth inhibition of human MCF7 cells after days by SRB assay
    [PMID: 17869098]
    MCF7 IC50
    9.6 μM
    Compound: Geldanamycin
    Cytotoxicity against human MCF7 cells by SRB assay
    Cytotoxicity against human MCF7 cells by SRB assay
    [PMID: 19560353]
    MCF7 IC50
    9.8 nM
    Compound: 5, GDA
    Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs
    Antiproliferative activity against human MCF7 cells expressing estrogen receptor after 72 hrs
    [PMID: 23648180]
    MDA-MB-231 IC50
    0.03 μM
    Compound: GA
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    [PMID: 27266997]
    MDA-MB-231 IC50
    0.05 μM
    Compound: 1, GA
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    MDA-MB-231 IC50
    0.05 μM
    Compound: GA
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
    [PMID: 25105924]
    MDA-MB-231 IC50
    0.06 μM
    Compound: GA
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by SRB assay
    [PMID: 29172085]
    MDA-MB-231 IC50
    0.11 μM
    Compound: Geldanamycin
    Anticancer activity against human MDA-MB-231 cells measured after 72 hrs by SRB assay
    Anticancer activity against human MDA-MB-231 cells measured after 72 hrs by SRB assay
    [PMID: 27283788]
    MDA-MB-231 IC50
    0.62 μM
    Compound: GM
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition by MTT assay
    [PMID: 32527461]
    NCI-H1975 GI50
    0.56 μM
    Compound: 1; GA
    Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells after 1 to 3 days by MTS assay
    Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells after 1 to 3 days by MTS assay
    [PMID: 27783977]
    NCI-H1975 GI50
    0.56 μM
    Compound: GA
    Antiproliferative activity against human NCI-H1975 cells after 72 hrs by Cell Titer 96 Aqueous One Solution cell proliferation assay
    Antiproliferative activity against human NCI-H1975 cells after 72 hrs by Cell Titer 96 Aqueous One Solution cell proliferation assay
    [PMID: 29202402]
    P19 IC50
    0.1 μM
    Compound: 1
    Cytotoxicity against mouse P19 cells after 18 hrs
    Cytotoxicity against mouse P19 cells after 18 hrs
    [PMID: 17442565]
    PC-3 IC50
    0.73 μM
    Compound: GDM
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human PC-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    RPMI-8226 GI50
    0.003 μM
    Compound: Geldanamycin
    Growth inhibition of human RPMI8226 cells after 72 hrs by MTS/PMS assay
    Growth inhibition of human RPMI8226 cells after 72 hrs by MTS/PMS assay
    [PMID: 29057043]
    Sf9 IC50
    74 nM
    Compound: Geldanamycin
    Displacement of GM-BODIPY from human full length HSP90 alpha expressed in baculovirus-infected Sf9 cells after 16 hrs by fluorescence polarization assay
    Displacement of GM-BODIPY from human full length HSP90 alpha expressed in baculovirus-infected Sf9 cells after 16 hrs by fluorescence polarization assay
    [PMID: 24751441]
    SK-BR-3 GI50
    0.43 μM
    Compound: 1; GA
    Antiproliferative activity against Her2-overexpressing human SKBR3 cells after 1 to 3 days by MTS assay
    Antiproliferative activity against Her2-overexpressing human SKBR3 cells after 1 to 3 days by MTS assay
    [PMID: 27783977]
    SK-BR-3 IC50
    0.87 μM
    Compound: GDM
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-BR-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    SK-BR-3 IC50
    41 nM
    Compound: GDM
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    Cytotoxicity against human SKBR3 cells after 72 hrs by celltiter-glo assay
    [PMID: 19405528]
    SK-BR-3 IC50
    8.5 nM
    Compound: 5, GDA
    Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 72 hrs
    Antiproliferative activity against estrogen receptor deficient human SKBR3 cells after 72 hrs
    [PMID: 23648180]
    SK-OV-3 IC50
    0.94 μM
    Compound: GDM
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    SMMC-7721 IC50
    0.11 μM
    Compound: GM
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SMMC7721 cells assessed as cell growth inhibition by MTT assay
    [PMID: 32527461]
    SNU-638 IC50
    0.03 μM
    Compound: Geldanamycin
    Anticancer activity against human SNU638 cells measured after 72 hrs by SRB assay
    Anticancer activity against human SNU638 cells measured after 72 hrs by SRB assay
    [PMID: 27283788]
    SW1990 IC50
    0.29 μM
    Compound: 1
    Antiproliferative activity against human SW1990 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    Antiproliferative activity against human SW1990 assessed as reduction in cell viability measured after 96 hrs by MTT assay
    [PMID: 27476419]
    SW480 IC50
    0.51 μM
    Compound: GM
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    Antiproliferative activity against human SW480 cells assessed as cell growth inhibition by MTT assay
    [PMID: 32527461]
    SW480 IC50
    310 nM
    Compound: 1, GA
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    Cytotoxicity against human SW480 cells after 72 hrs by MTT assay
    [PMID: 25277067]
    U-87MG ATCC EC50
    0.089 μM
    Compound: 1
    Antiproliferative activity against human U87 cells by luminescence assay
    Antiproliferative activity against human U87 cells by luminescence assay
    [PMID: 21605975]
    U-87MG ATCC IC50
    0.81 μM
    Compound: GDM
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    Antiproliferative activity against human U-87 MG cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
    [PMID: 32663707]
    In Vitro

    Geldanamycin significantly delays and reduces viperin expression, indicating that IRF3 is involved in viperin induction in RAW264.7 cells[1].
    Geldanamycin, a benzoquinone ansamycin, protected against neuronal injury induced by oxygen-glucose deprivation (OGD)/zVAD treatment in cultured primary neurons. More importantly, Geldanamycin decreases RIP1 protein level in a time and concentration-dependent manner. Geldanamycin also decreases the Hsp90 protein level, which causes instability of RIP1 protein, resulting in decreased RIP1 protein level but not RIP1 mRNA level after Geldanamycin treatment[2].
    Geldanamycin is identified as the first natural product inhibitor of Hsp90 that binds to the N-terminal ATPase domain of Hsp90 to inhibit its chaperone function, and significantly induces tumor cell death via an apoptotic mechanism[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Molecular Weight

    560.64

    Formula

    C29H40N2O9

    CAS No.
    Appearance

    Solid

    Color

    Light yellow to orange

    SMILES

    COC(C(C=C1NC(/C(C)=C/C=C/[C@H](OC)[C@@H](OC(N)=O)/C(C)=C/[C@H](C)[C@H]2O)=O)=O)=C(C[C@H](C[C@@H]2OC)C)C1=O

    Structure Classification
    Initial Source

    Streptomyces hygroscopicus

    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 25 mg/mL (44.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 1.7837 mL 8.9184 mL 17.8368 mL
    5 mM 0.3567 mL 1.7837 mL 3.5674 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (4.46 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.78%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 1.7837 mL 8.9184 mL 17.8368 mL 44.5919 mL
    5 mM 0.3567 mL 1.7837 mL 3.5674 mL 8.9184 mL
    10 mM 0.1784 mL 0.8918 mL 1.7837 mL 4.4592 mL
    15 mM 0.1189 mL 0.5946 mL 1.1891 mL 2.9728 mL
    20 mM 0.0892 mL 0.4459 mL 0.8918 mL 2.2296 mL
    25 mM 0.0713 mL 0.3567 mL 0.7135 mL 1.7837 mL
    30 mM 0.0595 mL 0.2973 mL 0.5946 mL 1.4864 mL
    40 mM 0.0446 mL 0.2230 mL 0.4459 mL 1.1148 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Salutation

    Applicant Name *

     

    Email Address *

    Phone Number *

     

    Organization Name *

    Department *

     

    Requested quantity *

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    Geldanamycin
    Cat. No.:
    HY-15230
    Quantity:
    MCE Japan Authorized Agent: